Summary of Key Points
Chinese innovative pharmaceutical companies have long been constrained by a lack of funding, forcing many promising projects to be sold at low prices before commercialization (a phenomenon known as “selling the young seedlings”), which results in dilution of founders’ equity and loss of research achievements. Now, a new model called “pharmaceutical licensing investment” has emerged. Investors like Royalty Pharma, the world’s largest licensor, do not provide equity but offer cash upfront in exchange for a share of future sales revenues after the drug is launched, effectively solving the last-minute funding challenges. Meanwhile, multinational pharmaceutical giants are also flocking to China to acquire high-quality innovative drugs. The global significance of Chinese innovation drugs is increasing, although this new model still needs time to gain widespread acceptance domestically.
The Pain of Chinese Innovative Pharmaceutical Companies: Lack of Funding Hindering Commercialization
The development of innovative drugs is a lengthy process that requires significant investment, especially during the final stages of commercialization (production, sales, and marketing), which can be particularly costly. Many small companies struggling with funding are forced to sell their most promising projects to larger firms at low prices to survive. This not only dilutes the founders’ equity but also sacrifices the hard work of their research teams. As Committee Member Zhang Wenhong pointed out, “China is capable of producing excellent drugs, so why can’t we keep them?”
Pharmaceutical Licensing Investment: A New Model That Doesn’t Require Equity
This model involves capital providing a cash payment to innovative companies without taking equity in exchange for a percentage of future sales revenues (similar to renting out property). Key differences from traditional financing include:
- No Equity Dilution: Licensing does not dilute the founders’ shares, allowing companies to retain control over their projects.
- Immediate Cash Flow: Companies can convert a portion of future revenue into cash, addressing their funding needs earlier in the process.
- Example: Royalty Pharma invested $700 million in a 3% license for the blockbuster drug Humira and later made a substantial profit. BeiGene sold most of the overseas licensing rights for one of its drugs last year, receiving $885 million in cash.
This model is particularly suitable for companies with promising drugs but limited cash flow, effectively bridging the final gap in funding.
Royalty Pharma Enters China: Global Investors Eyeing the Chinese Market
Royalty Pharma, the largest licensor in the world, has recently opened an office in Hong Kong to target the Chinese market. Why China?
- Great Potential: The value of Chinese innovation drugs is expected to exceed $130 billion by 2025, ten times that of 2021, attracting increasing attention from multinational companies.
- Focus on Late-Stage Projects: They invest in drugs that are close to market approval (with over 90% success rates), unlike other firms that often purchase early-stage projects.
- Value for Chinese Companies: This model provides flexible funding without equity dilution, helping more drugs to be developed and launched domestically.
Multinational Pharmaceutical Giants Flocking to China
Many CEOs from companies like Novo Nordisk, Pfizer, and UCB have recently visited China in search of high-quality innovative projects. Why?
- China’s Advantages: Faster development speeds and lower costs compared to Europe; 28 out of 81 global innovative drugs in 2024 came from China (compared to 18 from Europe).
- Growing Market Share: China’s share of early-stage drug development projects has risen from 8% in 2015 to 32% in 2024, approaching that of the United States (37%).
- Specific Actions: Novo Nordisk is collaborating on weight-loss drugs with local companies, UCB is acquiring Chinese innovative assets, and Pfizer plans to actively invest in Chinese projects.
Challenges and Future Prospects
Although licensing investment is a mature market globally (with annual transactions exceeding $10 billion), it is still relatively rare in China:
- Cultural Reservations: Companies are accustomed to equity financing and hesitate to try new models.
- Higher Costs: Licensing requires giving up 15%-20% of potential long-term value, which may be more expensive than traditional financing methods.
- Expertise Required: Companies need professional teams to assess the commercial potential of drugs.
However, the prospects are promising. As Chinese innovation drugs gain more prominence in the global value chain, more companies will adopt this model. Over time, a local licensing investment ecosystem could emerge, as any solution to the funding challenge is likely to be embraced by the market.
In summary, pharmaceutical licensing investment offers new funding options for Chinese innovative firms, and the interest from multinational companies highlights the global value of these drugs. While this new model needs time to become widespread, it represents a crucial step towards overcoming funding barriers and preserving valuable research efforts.